Biopolymer-Capped Pyrazinamide-Loaded Colloidosomes: In Vitro Characterization and Bioavailability Studies

Avi Singh; Sabya Sachi Das; Janne Ruokolainen; Kavindra Kumar Kesari; Sandeep Kumar Singh

doi:10.1021/acsomega.3c03135

Biopolymer-Capped Pyrazinamide-Loaded Colloidosomes: In Vitro Characterization and Bioavailability Studies

ACS Omega. 2023 Jul 7;8(28):25515-25524. doi: 10.1021/acsomega.3c03135. eCollection 2023 Jul 18.

Authors

Avi Singh¹, Sabya Sachi Das², Janne Ruokolainen³, Kavindra Kumar Kesari^{3

4}, Sandeep Kumar Singh¹

Affiliations

¹ Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India.
² School of Pharmaceutical and Population Health Informatics, DIT University, Dehradun 248009, Uttarakhand, India.
³ Department of Applied Physics, School of Science, Aalto University, Espoo 00076, Finland.
⁴ Faculty of Biological and Environmental Sciences, University of Helsinki, Viikinkaari 1, 00790 Helsinki, Finland.

Abstract

This study aimed to prepare colloidosome particles loaded with pyrazinamide (PZA). These drug-loaded colloidosomes were prepared using an in situ gelation technique using a central composite design with a shell made of calcium carbonate (CaCO₃) particles. Optimal amounts of 150 mg of CaCO₃, sodium alginate (2%), and 400 mg of poly(3-hydroxybutyrate-co-3-hydroxy valerate) (PHBV) concentration resulted in the maximum drug loading and efficient release profile. Field emission scanning electron microscopy results showed spherical porous particles with a good coating of the PHBV polymer. Additionally, Fourier transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), thermogravimetric and differential thermal analysis (TGA-DTA), and X-ray diffraction (XRD) analysis showed good compatibility between the drug and excipients. The pharmacokinetic studies demonstrated that the drug-loaded colloidosomes resulted in 4.26 times higher plasma drug concentrations with C_max values of 32.386 ± 2.744 mcg/mL (PZA solution) and 115.868 ± 53.581 mcg/mL (PZA-loaded colloidosomes) and AUC_0-t values of 61.24 mcg-h/mL (PZA solution) and 260.9 mcg-h/mL (PZA-loaded colloidosomes), indicating that colloidosomes have the potential to be effective drug carriers for delivering PZA to the target site.